Title : TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).

Pub. Date : 2020 May 10

PMID : 32097092






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). Cyclophosphamide BRCA1 DNA repair associated Homo sapiens